ArticlePloS one2014
Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.International journal of molecular sciences · 2020Pooled it
- Biomarker concordance between primary colorectal cancer and its metastases.EBioMedicine · 2019Pooled it
- Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.Journal of translational medicine · 2026Review
- The different clonal origins of metachronous and synchronous metastases.Journal of cancer research and clinical oncology · 2023Article
- Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Nature communications · 2023Article
- Comparison of genetic variation between primary colorectal cancer and metastatic peritoneal cancer.Genes & genomics · 2023Article
- Usefulness of pyruvate dehydrogenase-E1α expression to determine SUVmax cut-off value of [Scientific reports · 2023Article
- Metastatic Lesions of the Brain and Spine.Advances in experimental medicine and biology · 2023Article
- Uncovering novel mutational signatures byCell genomics · 2022Article
- Comparison of sampling methods for next generation sequencing for patients with lung cancer.Cancer medicine · 2022Article
- Roles of ARID1A variations in colorectal cancer: a collaborative review.Molecular medicine (Cambridge, Mass.) · 2022Review
- Mutational landscape of paired primary and synchronous metastatic lymph node in chemotherapy naive gallbladder cancer.Molecular biology reports · 2022Article
- Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.PloS one · 2022Article
- Recommendations for Specimen and Therapy Selection in Colorectal Cancer.Oncology and therapy · 2021Article
- Assessment of oncogenic role of intestinal microbiota in colorectal cancer patients.Journal of gastrointestinal cancer · 2021Article
- Article
- Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?Translational oncology · 2021Review
- Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.Clinical and translational medicine · 2021Article
- Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas.Frontiers in oncology · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 50% of patients with primary colorectal carcinoma develop liver metastases. Understanding the genetic differences between primary colon cancer and their metastases to the liver is essential for devising a better therapeutic approach for this disease. We performed whole exome sequencing and copy number analysis for 15 triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis. We analyzed the similarities and differences between primary colorectal carcinoma and matched liver metastases in regards to somatic mutations and somatic copy number alterationss. The genomic profiling demonstrated mutations in APC(73%), KRAS (33%), ARID1A and PIK3CA (6.7%) genes between primary colorectal and metastatic liver tumors. TP53 mutation was observed in 47% of the primary samples and 67% in liver metastatic samples. The grouped pairs, in hierarchical clustering showed similar somatic copy number alteration patterns, in contrast to the ungrouped pairs. Many mutations (including those of known key cancer driver genes) were shared in the grouped pairs. The ungrouped pairs exhibited distinct mutation patterns with no shared mutations in key driver genes. Four ungrouped liver metastasis samples had mutations in DNA mismatch repair genes along with hypermutations and a substantial number of copy number alterations. Our results suggest that about half of the metastatic colorectal carcinoma had the same clonal origin with their primary colorectal carcinomas, whereas remaining cases were genetically distinct from their primary carcinomas. These findings underscore the need to evaluate metastatic lesions separately for optimized therapy, rather than to extrapolate from primary tumor data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.